Nasonex

ApprovedSmall molecule

Teva

Nasonex is one of 97 small molecule programs targeting Obstructive Sleep Apnea. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Obstructive Sleep ApneaActive, not recruiting

Allergic RhinitisActive, not recruiting

Seasonal Allergic RhinitisActive, not recruiting

Obstructive Sleep ApneaApproved

Active, not recruiting

Allergic RhinitisPreclinical

Active, not recruiting

Seasonal Allergic RhinitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

271 competitors in Allergic Rhinitis

#DrugCompanyPhaseTrials

Comparator: Statins

Merck & Co.

Phase 3

2 2

Active Comparator

Moderna

Phase 3

1 3

Nasonex

Teva

Approved

1 4

Standard Adjuvant ET

Eli Lilly

Phase 3

1 5

Flonase

Teva

Phase 3

1 6

Allegra-D

Pfizer

Phase 3

3 7

Asmanex

Novartis

Preclinical

12 8

Product CM9241GRU

AAche Laboratorios Farmaceuticos S.A.

Phase 3

1 9

Veramyst

Singulair

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Seasonal Allergic Rhinitis2 trials

Study to Compare the Therapeutic Equivalence of Mometasone Furoate Nasal Spray, 50 mcg With Nasonex Nasal Spray in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

Completed·AAmneal Pharmaceuticals, LLC·Phase 3·NCT02125253·811 enrolled

A Safety and Bioequivalence of a Mometasone Nasal Spray, 50 mcg/Actuation Compared With Nasonex® Nasal Spray 50 mcg/Actuation in the Relief of the Symptoms of Seasonal Allergic Rhinitis (SAR)

Completed·PPadagis LLC·Phase 3·NCT01673659·1,220 enrolled

Allergic Rhinitis1 trial

The Efficacy Of Elonide Nasal Corticosteroids In Managing Allergic Rhinitis

Completed·NNational University of Malaysia·N/A·NCT05912192·163 enrolled

Corticosteroids1 trial

The Efficacy Of Rhinophototherapy Compared To Intranasal Corticosteroids On The Nasal Mucosa

Recruiting·NNational University of Malaysia·N/A·NCT05919316·40 enrolled

Obstructive Sleep Apnea1 trial

Intranasal Steroids for the Treatment of Nocturnal Enuresis With Associated Obstructive Sleep Apnea

Withdrawn·UUniversity of Alberta·Phase 4·NCT01861145

Unspecified1 trial

Clinical Equivalence Study of Mometasone Nasal Spray, 50 Mcg/Actuation

Completed· Teva logo

Teva·Phase 1/2·NCT01523236·800 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Nasonex. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nasonex compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nasonex. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Teva company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Teva

Nasonex

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Seasonal Allergic Rhinitis2 trials

Allergic Rhinitis1 trial

Corticosteroids1 trial

Obstructive Sleep Apnea1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News